12 Nov PROTECT Study for Newly Diagnosed T1D Ages 8-17
Patients ages 8 – 17 with newly diagnosed type 1 diabetes have an opportunity to participate in the PROTECT Study, a clinical trial to see if a study drug called teplizumab can safely preserve insulin-producing cells.
Previous clinical studies have suggested a benefit of teplizumab in prolonging insulin production in people recently diagnosed with T1D. A recent landmark study showed that this drug can delay the development of T1D in at-risk individuals. The PROTECT Study is evaluating how well teplizumab works in children and adolescents who have been recently diagnosed with T1D.
Your child may be eligible to participate if he/she:
– is 8-17 years old
– has been very recently diagnosed with Type 1 Diabetes: please contact Benaroya Research Institute within 2-3 weeks of diagnosis!
– is in good general health
If you are found to be eligible, you will visit our Seattle clinic for all appointments and visits. Travel and lodging expenses can be covered for non-local participants.
This study is only open to people within a very short time after diagnosis, so if you are interested, please contact us right away!
Additional Study Details
Full Study Title
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Carla Greenbaum, MD
Accepts Healthy Volunteers?
Benaroya Research Institute
1201 Ninth Avenue
Seattle, Washington 98101